Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era

被引：13
作者：
Butler, L. A. [1 ,2 ]
Tam, C. S. [1 ,2 ,3 ,4 ]
Seymour, J. F. [1 ,2 ,4 ]
机构：
[1] Peter MacCallum Canc Ctr, 305 Grattan St, Melbourne, Vic 3000, Australia
[2] Victorian Comprehens Canc Ctr, 305 Grattan St, Melbourne, Vic 3000, Australia
[3] St Vincents Hosp, 41 Victoria Parade, Fitzroy, Vic 3065, Australia
[4] Univ Melbourne, Fac Med, Bldg 181,Grattan St, Parkville, Vic 3052, Australia
来源：
BLOOD REVIEWS | 2017年 / 31卷 / 05期
关键词：
Obinutuzumab; Ocaratuzumab; Ofatumumab; Rituximab; Ublituximab; Veltuzumab; PREVIOUSLY UNTREATED PATIENTS; DEPENDENT CELLULAR CYTOTOXICITY; LOW-DOSE FLUDARABINE; MONOCLONAL-ANTIBODY; INITIAL THERAPY; PLUS RITUXIMAB; OPEN-LABEL; 1ST-LINE TREATMENT; FREE SURVIVAL; PHASE; 1/2;
D O I：
10.1016/j.blre.2017.05.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The anti-CD20 antibodies represent a major advancement in the therapeutic options available for chronic lymphocytic leukemia. The addition of rituximab, ofatumumab and obinutuzumab to various chemotherapy regimens has led to considerable improvements in both response and survival. Ocaraturtimab, veltuzumab and ublituximab are currently being explored within the trial setting. We review the current status of these antibodies, and discuss how their mechanisms of action may impact on the choice of combinations with novel small molecule agents.
引用
收藏
页码：318 / 327
页数：10
相关论文
共 82 条
[1]   Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].
Advani, Ranjana H. ;
Buggy, Joseph J. ;
Sharman, Jeff P. ;
Smith, Sonali M. ;
Boyd, Thomas E. ;
Grant, Barbara ;
Kolibaba, Kathryn S. ;
Furman, Richard R. ;
Rodriguez, Sara ;
Chang, Betty Y. ;
Sukbuntherng, Juthamas ;
Izumi, Raquel ;
Hamdy, Ahmed ;
Hedrick, Eric ;
Fowler, Nathan H. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94
[2]   The future of anti-CD20 monoclonal antibodies: are we making progress? [J].
Alduaij, Waleed ;
Illidge, Tim M. .
BLOOD, 2011, 117 (11) :2993-3001
[3]  
[Anonymous], FINAL RESULTS MULTIC
[4]  
[Anonymous], VENETOCLAX ABT 199 G
[5]  
[Anonymous], CC 122 EXHIBITS GREA
[6]  
[Anonymous], 2016, ANN ONCOL
[7]  
[Anonymous], J LEUK
[8]  
[Anonymous], GREEN STUDY PRELIMIN
[9]  
[Anonymous], RESULTS PHASE 3 RAND
[10]  
[Anonymous], RANDOMIZED MULTICENT
123456789